Eli Lilly (LLY) stock rose slightly early Thursday after the drug giant reported adjusted earnings of $5.32 per share on $13.53 billion in fourth-quarter sales.
↑ X NOW PLAYING The Weight-Loss Drug Market Is Hot. Which Medical Stock Will Win The Battle For Supremacy?On average, analysts polled by FactSet expected Lilly to earn $5.06 per share and report $13.55 billion in sales. In the year-earlier period, the pharma company reported earnings of $2.49 per share on $9.35 billion in sales.
Weight-loss drug Zepbound generated $1.91 billion, while diabetes treatment Mounjaro brought in $3.53 billion. Analysts called for a respective $1.99 billion and $3.63 billion in sales.
For the year, Eli Lilly guided to adjusted EPS of $22.50-$24 on revenue of $58 billion-$61 billion, with the midpoints both above consensus. The Street called for adjusted earnings of $22.76 per share and $58.77 billion in sales.
In premarket trades on the stock market today, Eli Lilly stock rose 1.2%. Shares are consolidating with a buy point at 972.53, according to MarketSurge. On Wednesday, LLY stock closed above its 200-day line for the first time in nearly three months.
More to follow.
YOU MAY ALSO LIKE:
Novo Surges As Ozempic Drives Fourth-Quarter Beat. But Supply Shortages Expected.
How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat
Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists
See IBD Stock Lists & Get Pass/Fail Ratings For All Your Stocks With IBD Digital
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.